Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Introduction Glucagon as an Anti-Obesity Agent Obesity is a leading cause of global morbidity and death
"GLP-1 receptor agonists in the treatment of type 2 diabetes state-of-the-art." Molecular Metabolism, vol
Take, for example, the following substances which WADA has classified as beta-agonists: salbutamol, formoterol, salmeterol and higenamine
The current global market size for anti-obesity medications (such as GLP-1RAs) was estimated by Goldman Sachs 7 to be c.$6bn
This placebo-controlled study in more than 6000 subjects with T2DM and acute coronary syndrome demonstrated the cardiovascular safety of chronic exposure to lixisenatide
Additionally, the evidence base for efficacy and safety specifically in BED populations remains limited
US$ 21.37
US$ 19.99
US$ 26.27
US$ 24.58
US$ 28.42
